BPAUS

Company Overview

Snapshot

Founded in February 2019 by Yuri Tselicov and Evgeny Borovsky, BPAUS operates with 1–10 employees. The company has raised $233K across one funding round from one investor. In July 2022, Amir Ayal invested in BPAUS.

Business overview

BPAUS develops a digital, child-oriented platform designed for the diagnosis, assessment, treatment, and ongoing monitoring of autism. The platform integrates established methods such as behavioral analysis, speech-language pathology, occupational therapy, emotional therapy, and physiotherapy to create optimized treatment plans. BPAUS aims to enhance the capacity of healthcare providers and clinics to deliver comprehensive treatment to a broader audience, thereby improving efficiency and reducing costs. The company operates within the Digital Health and Medical Technologies sector, specifically focusing on Digital Healthcare and Digital Therapeutics, and serves healthcare providers globally.

Strategic signal

In July 2022, BPAUS secured an investment from Amir Ayal, signaling continued investor confidence in its digital platform for autism assessment and treatment. This capital infusion supports the company's mission to expand its reach and improve access to specialized care, highlighting a strategic validation of its approach within the digital therapeutics market.

Company Intelligence Q&A

When was BPAUS founded and by whom?

BPAUS was founded in February 2019 by Yuri Tselicov and Evgeny Borovsky.

What is the primary focus of BPAUS's digital platform?

BPAUS's digital platform focuses on the early assessment, treatment, and ongoing monitoring of autism, incorporating various therapeutic methods.

Which investor participated in BPAUS's funding round?

In July 2022, Amir Ayal invested $233K in BPAUS, according to a report from Mako.co.il.

What is BPAUS's primary sector?

BPAUS operates in the Health Tech & Life Sciences sector, with a focus on Digital Healthcare and Digital Therapeutics.

What markets does BPAUS target with its platform?

BPAUS targets global markets, including North America, the United States, and Europe, aiming to assist healthcare providers and clinics.